A Faster Finish May Depend On A Better Start – EMA's PRIME Program
This article was originally published in The Pink Sheet Daily
Executive Summary
EMA officials spotlight need to improve clinical development plans in the early stages, with agency exec director Rasi saying many trials are "useless." They shy away from predicting timelines or goals for quicker reviews.
You may also be interested in...
European Notebook: All Change In The C-Suites; EMA PRIME Starts; French Experts Recommend Phase I Changes
Once-in-a-decade leadership changes stack up in Europe’s big pharma companies as the region aims for quicker and more certain drug development, although following a recent fatality an expert committee is advising caution during dose-escalation in Phase I studies.
PRIME Time: Smaller Companies In Focus As EMA Launches Priority Medicines Scheme
In exceptional cases, smaller and medium-sized companies might obtain PRIME designation in proof of principle stage, underscoring the expectation that they will particularly benefit from the program.
PRIME Time: Smaller Companies In Focus As EMA Launches Priority Medicines Scheme
In exceptional cases, smaller and medium-sized companies might obtain PRIME designation in proof of principle stage, underscoring the expectation that they will particularly benefit from the program.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: